Roche Holding AG (DELISTED) (RHHVF:DL)
432.80
+29.91
(+7.42%)
USD |
OTCM |
Mar 17, 16:03
Roche PS Ratio : 4.689 for March 17, 2026
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PS Ratio Data
| Date | Value |
|---|---|
| March 16, 2026 | 4.365 |
| March 13, 2026 | 4.538 |
| March 12, 2026 | 4.659 |
| March 11, 2026 | 4.623 |
| March 10, 2026 | 4.748 |
| March 09, 2026 | 4.745 |
| March 06, 2026 | 4.757 |
| March 05, 2026 | 4.865 |
| March 04, 2026 | 5.029 |
| March 03, 2026 | 4.900 |
| March 02, 2026 | 5.099 |
| February 27, 2026 | 5.200 |
| February 26, 2026 | 5.200 |
| February 25, 2026 | 5.125 |
| February 24, 2026 | 5.228 |
| February 23, 2026 | 5.200 |
| February 20, 2026 | 5.200 |
| February 19, 2026 | 5.173 |
| February 18, 2026 | 5.188 |
| February 17, 2026 | 5.277 |
| February 13, 2026 | 5.186 |
| February 12, 2026 | 5.052 |
| February 11, 2026 | 5.056 |
| February 10, 2026 | 5.038 |
| February 09, 2026 | 4.924 |
| Date | Value |
|---|---|
| February 06, 2026 | 4.987 |
| February 05, 2026 | 4.951 |
| February 04, 2026 | 4.968 |
| February 03, 2026 | 4.899 |
| February 02, 2026 | 4.925 |
| January 30, 2026 | 4.801 |
| January 29, 2026 | 5.077 |
| January 28, 2026 | 4.594 |
| January 27, 2026 | 4.887 |
| January 26, 2026 | 4.834 |
| January 23, 2026 | 4.800 |
| January 22, 2026 | 4.719 |
| January 21, 2026 | 4.753 |
| January 20, 2026 | 4.765 |
| January 16, 2026 | 4.758 |
| January 15, 2026 | 4.783 |
| January 14, 2026 | 4.579 |
| January 13, 2026 | 4.615 |
| January 12, 2026 | 4.624 |
| January 09, 2026 | 4.567 |
| January 08, 2026 | 4.550 |
| January 07, 2026 | 4.564 |
| January 06, 2026 | 4.518 |
| January 05, 2026 | 4.469 |
| January 02, 2026 | 4.375 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| Galderma Group AG | 9.415 |
| EvoNext Holdings SA | -- |
| Kuros Biosciences Ltd. | 6.986 |
| Basilea Pharmaceutica AG | 2.940 |
PS Ratio Related Metrics
| PE Ratio | 22.52 |
| PEG Ratio | 1.063 |
| Price to Free Cash Flow | 23.06 |
| Price | 432.80 |
| Earnings Yield | 4.44% |
| Market Cap | 344.34B |
| PEGY Ratio | 0.9273 |
| Operating PE Ratio | 15.26 |
| Normalized PE Ratio | 19.31 |